glp-1 telehealth crackdown news today Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight FDA takes aim at telehealth

This creates a vicious cycle

If youre looking to find out which GLP-1 is best for weight loss, youve come to the right place

SURMOUNT-3, combining tirzepatide with intensive lifestyle intervention, demonstrated 26.6% total weight loss

Key Takeaways Starting dose: 2mg once weekly for the first 4 weeks to assess tolerance Titration schedule: Increase every 4 weeks: 2mg 4mg 8mg 12mg (max) Half-life: Approximately 6 days, reaching steady state in 4-5 weeks Injection frequency: Once weekly on the same day each week Microdosing option: Some users split doses for improved tolerability Investigational Drug: Retatrutide is NOT FDA-approved and is currently only available through clinical trials

Evidence and UK Guidance Polycystic ovary syndrome (PCOS) affects approximately 10% of women of reproductive age in the UK, causing hormonal imbalances, irregular periods, and significant metabolic complications including insulin resistance and increased diabetes risk

doi:10.1677/joe.0.1300267 289